Table 2.

Summary of main results

	25% target		50% target		75% target
	Standard of care	MDMA-AT	Standard of care	MDMA-AT	Standard of care	MDMA-AT
Deaths	191,199	147,581	347,618	268,850	475,175	368,243
QALYs	6,491,139	9,818,489	11,723,620	17,736,175	15,917,517	24,085,168
Costs (billions US$)	256	147	462	266	628	361
Incremental deaths averted	43,618		78,768		106,932
Incremental QALYs	3,327,350		6,012,555		8,167,652
Incremental cost-savings (US$)	$109 billion		$196 billion		$266 billion

Incremental cost-effectiveness ratios were not calculated because MDMA-AT was lower in cost and produced more health benefits than standard of care for three MDMA-AT treatment targets. Costs are in billions US$

MDMA-AT methylenedioxymethamphetamine-assisted psychotherapy, QALY quality-adjusted life year